open access

Vol 9, No 1 (2013)
Review paper
Published online: 2013-04-02
Get Citation

Eribulin in the treatment of advanced breast cancer

Aleksandra Łacko
Onkol. Prak. Klin 2013;9(1):10-14.

open access

Vol 9, No 1 (2013)
REVIEW ARTICLES
Published online: 2013-04-02

Abstract

Despite the improvement in the systemic treatment of recurrent or metastatic breast cancer and availability of hormonal and targeted agents, chemotherapy remains a mainstay of treatment of advanced breast cancer.  Treatment choices for women with advanced breast cancer include several single agents agents and combination regiments. Anthracyclines, taxanes and anti- HER-2 agents, in women with HER-2 positive tumors, are recommended in the initial treatment. For subsequent lines of chemotherapy fluoropyrimidines, gemcytabine, vinorelbine and eribulin are approved in Europe. Eribulin is novel microtubule inhibitor active in a heavily pretreated patients. Phase III clinical trial showed statistically significant improvement of overall survival for eribulin compared to the treatment of physicion’s choice in this population. This article is aimed to present current data regarding eribulin in the management of advanced breast cancer.

Abstract

Despite the improvement in the systemic treatment of recurrent or metastatic breast cancer and availability of hormonal and targeted agents, chemotherapy remains a mainstay of treatment of advanced breast cancer.  Treatment choices for women with advanced breast cancer include several single agents agents and combination regiments. Anthracyclines, taxanes and anti- HER-2 agents, in women with HER-2 positive tumors, are recommended in the initial treatment. For subsequent lines of chemotherapy fluoropyrimidines, gemcytabine, vinorelbine and eribulin are approved in Europe. Eribulin is novel microtubule inhibitor active in a heavily pretreated patients. Phase III clinical trial showed statistically significant improvement of overall survival for eribulin compared to the treatment of physicion’s choice in this population. This article is aimed to present current data regarding eribulin in the management of advanced breast cancer.
Get Citation

Keywords

breast cancer; chemotherapy; eribulin

About this article
Title

Eribulin in the treatment of advanced breast cancer

Journal

Oncology in Clinical Practice

Issue

Vol 9, No 1 (2013)

Article type

Review paper

Pages

10-14

Published online

2013-04-02

Bibliographic record

Onkol. Prak. Klin 2013;9(1):10-14.

Keywords

breast cancer
chemotherapy
eribulin

Authors

Aleksandra Łacko

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl